期刊文献+

干细胞移植治疗多次输亲属血的重症再障 被引量:1

Stem Cell Transplantation Treatment in Severe Aplastic Anemia from Mutiple Transfusions of Relatives Blood
下载PDF
导出
摘要 目的探讨造血干细胞移植对多次输亲属血的重症再障患者的疗效。 方法 1例曾有 5次输其父亲及兄弟外周血的重症再障患者 ,应用DNA指纹检测法确认HLA配型与患者完全相符的孪生兄弟为同卵双生 ,采用环磷酰胺、全血淋巴结照射和抗胸腺球蛋白 (CY +TBI +ATG)为预处理方案 ,以环胞霉素A和氨甲喋呤 (CsA +MTX)预防移植物抗宿主排异反应 (GVHD)的发生。 结果患者于移植后第 7d及第 10d外周血白细胞计数分别升至 >0 .5× 10 9/L及 >1.0× 10 9/L。患者的外周血血小板计数分别于移植后第 12d及 2 6d升至 >2 0× 10 9/L和 >5 0×10 9/L。骨髓细胞学检查显示粒、红、巨系均增生活跃 ,为增生性骨髓象。 结论以CY +TBI +ATG为预处理方案的造血干细胞移植可预防急性超强GVHD的发生 。 Objective To present the experience of syngeneic stem cell transplantation (bone marrow transplantation following peripheral blood stem cell transplantation) for a transfused patient with severe aplastic anemia. Methods We report our experience of syngeneic stem cell transplantation for a patient with aplastic anemia who had 5 consecutive transfusion from his brother and parents. The patient was conditioned with TBI, clophosphamide (CY) and antithymocyte globulin (ATG). For GVHD prophylaxis the patient received MTX and CsA. The patient had sustained engraftment. Results The time for granulocyte >0.5×10 9/L and >1.0×10 9/L were day 7 and day 10. The time for recovery of a platelet count >20×10 9/L and >50×10 9/L were day 12 and day 26. GVHD did not occur in the patient. Conclusion The combination of CY+TBI+ATG is an effective, well-tolerated conditioning regimen for stem cell transplantation in the transfused aplastic anemia patient, especially in the patient who had been transfused from his relatives.
出处 《上海第二医科大学学报》 CSCD 2001年第4期347-349,共3页 Acta Universitatis Medicinalis Secondae Shanghai
关键词 重症再生障碍性贫血 干细胞移植 治疗 移植物抗宿主排异反应 stem cell transplantation aplastic anemia GVHD
  • 相关文献

参考文献3

  • 1Deeg H J,Blood,1998年,91卷,3637页
  • 2Deeg H J,Blood,1996年,87卷,386页
  • 3Kersey J H,Trans plantation,1980年,29卷,388页

同被引文献18

  • 1中华医学会儿科学分会血液学组.重型地中海贫血的诊断和治疗指南[J].中华儿科杂志,2010,48:186-188.
  • 2张新华,黄有文.血液病诊断及疗效标准//张之南,沈悌,主编.血液病诊断与疗效标准.3版.北京:科学技术出版社,2007:29-34.
  • 3Cappelini M-D, Cohen A, Eleftheriou A, et al. Guidelines for the clinical management of thalassaemia. 2th ed. Nicosia Cyprus: Thalassaemia International Federation, 2008:23-27.
  • 4Marina CC, Emmanuel P, Olivier N, et al. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature, 2010, 467:318-332.
  • 5张新华,尹晓林.重型β地中海贫血的处置和预后//徐湘民,主编.地中海贫血预防控制操作指南.北京:人民军医出版社,2011:48-52.
  • 6龙桂芳,赖永榕.地中海贫血的临床治疗//张俊武,龙桂芳,主编.血红蛋白与血红蛋白病.南宁:广西科学技术出版社,2003:307-314.
  • 7Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica, 2004, 89 : 1187-1193.
  • 8Sloan SR. Immunologic responders to red blood cell transfusions. Hematology Education, the education program for the annual congress of the European Hematology Association, 2011, 5: 381-384.
  • 9Ambruso DR, Le T, Cole Laura, et al. Extended matching of red cell antigens for patients with sickle cell anenia decreases the rate of alloimmunization. Blood (ASH Annual Meeting Abstracts), 2007, 110:3389.
  • 10Cunningham M J, Macklin EA, Singer ST, et al. Red blood cell allo and autoantibody production in patients in the thalassemia clinical research network. Blood (ASH Annual Meeting Abstracts), 2005, 106:1890.

引证文献1

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部